Blue Stream Laboratories Adds Capacity
News Nov 05, 2015
Blue Stream Laboratories is expanding into new office and lab space, adjacent to its current facility, to handle the continued growth of its biosimilars services. Last year, the company moved into new space in Woburn to double the capacity of its prior Cambridge facility.
Blue Stream will exhibit at Booth 8 at the Well Characterized Biologicals Conference from Nov. 9-10 at the Hyatt Regency Reston VA.
Having provided characterization services for 10 of the top biosimilar products in development, Blue Stream offers a complete suite of analytical solutions for biosimilar product development from initial product screening to biosimilar/originator comparability to comprehensive characterization including primary and secondary/tertiary structure, glycosylation/PTMs, and activity.
The biosimilar segment continues to perform well for the company. In 2014, Blue Stream recorded a 60 percent increase in revenue over the prior year, along with a 50 percent increase in facility size, and a 30 percent expansion of its research and development capabilities. This growth was significantly driven by Blue Stream’s biosimilars services.
“The market for biosimilars continues to grow, with consensus of reaching at least $20 billion within the next few years. Blue Stream has significant biosimilar expertise, and we continue to invest in the people, equipment and infrastructure to develop innovative methods, improve quality and extend our expertise,” said William Rash, VP, Sales and Marketing of Blue Stream Laboratories.
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE